Skip to content

US · EQ · BIOTECHNOLOGY

Equillium, Inc. (EQ) intrinsic value and stock valuation

$1.06as of 2026-11-21 · Mkt cap 74.95M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Equillium, Inc. DCF and intrinsic value

InvestorsCraft values EQ with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from EQ’s statements →

Equillium, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology La Jolla, CA 92037 equilliumbio.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-22.4M
20172025
Free cash flow
-$-22.79M
20172025
Total equity
$28.6M-16.4% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$41.1M$36.1M$15.8M$0.00
Operating income-$-23.63M-$-8.27M-$-14.52M-$-62.08M-$-37.79M
Net income-$-22.4M-$-8.07M-$-13.34M-$-62.43M-$-38.98M
EPSd-$-243.8K-$-228.22K-$-384.11K-$-1.85M-$-1.35M
Operating cash flow-$-22.75M-$-19.03M-$-21.78M-$-8.73M-$-32.08M
Capital expenditure-$-50K-$-90K-$-50K-$-280K-$-60K
Free cash flow-$-22.79M-$-19.11M-$-21.83M-$-9.01M-$-32.14M
Total assets$31.9M$25.6M$50.5M$78.4M$85.4M
Total debt$720K$380K$820K$10.2M$11.8M
Net debt-$-29.56M-$-17.7M-$-22.39M-$-48.92M-$-38.58M
Total equity$28.6M$19.1M$22.6M$31.9M$66.5M
Cash and short-term investments$30.3M$22.6M$40.9M$71M$80.7M
Income statement
20252024202320222021
Revenue$0.00$41.1M$36.1M$15.8M$0.00
Cost of revenue$120K$0.00$0.00$0.00$0.00
Gross profit-$-120K$41.1M$36.1M$15.8M$0.00
Research and development expenses$12.8M$37.4M$37M$37.6M$26.4M
Selling, general and administrative expenses$10.8M$11.9M$13.6M$17.2M$11.4M
Other expenses$0.00$0.00$0.00$23.1M$0.00
Operating expenses$23.6M$49.4M$50.6M$77.8M$37.8M
Cost and expenses$23.6M$49.4M$50.6M$77.8M$37.8M
Interest income$830K$1.38M$2.33M$420K$60K
Interest expense$0.00$0.00$490K$1.05M$1.07M
Depreciation and amortization$120K$140K$130K$120K$70K
Ebitda-$-22.28M-$-7.57M-$-12.14M-$-61.26M-$-37.91M
Operating income-$-23.63M-$-8.27M-$-14.52M-$-62.08M-$-37.79M
Total other income/expenses, net$1.24M$560K$1.77M-$-350K-$-1.27M
Income before tax-$-22.4M-$-7.71M-$-12.76M-$-62.43M-$-39.05M
Income tax expense$0.00$360K$580K$0.00$0.00
Net income-$-22.4M-$-8.07M-$-13.34M-$-62.43M-$-38.98M
Weighted average shares outstanding$91.9M$35.4M$34.7M$33.7M$28.8M
Weighted average diluted shares outstanding$91.9M$35.4M$34.7M$33.7M$28.8M
Balance sheet
20252024202320222021
Cash and short-term investments$30.3M$22.6M$40.9M$71M$80.7M
Net receivables$110K$1.14M$6.29M$4.11M$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$30.3M$25M$49.4M$76.7M$83.4M
Property, plant and equipment, net$660K$630K$1.11M$1.58M$1.88M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$660K$630K$1.18M$1.69M$2.04M
Total assets$31.9M$25.6M$50.5M$78.4M$85.4M
Accounts payable$760K$2.68M$4.71M$3.98M$1.23M
Short-term debt$360K$200K$440K$6.12M$1.8M
Deferred revenue$0.00$0.00$15.7M$14.7M$0.00
Total current liabilities$2.93M$6.36M$27.6M$32M$8.91M
Long-term debt$360K$190K$380K$4.06M$9.98M
Deferred revenue, non-current$0.00$0.00$0.00$10.4M$0.00
Total non-current liabilities$360K$190K$380K$14.4M$9.98M
Capital lease obligations$0.00$190K$820K$1.23M$1.61M
Total liabilities$3.29M$6.54M$28M$46.5M$18.9M
Common stock$10K$0.00$0.00$0.00$0.00
Retained earnings-$-216.21M-$-193.81M-$-185.74M-$-172.41M-$-109.98M
Accumulated other comprehensive income (loss)$360K$780K$140K$80K-$-140K
Total equity$28.6M$19.1M$22.6M$31.9M$66.5M
Total investments$0.00$4.49M$17.7M$11.9M$30.3M
Total debt$720K$380K$820K$10.2M$11.8M
Net debt-$-29.56M-$-17.7M-$-22.39M-$-48.92M-$-38.58M
Cash flow statement
20252024202320222021
Net income-$-22.4M-$-8.07M-$-13.34M-$-62.43M-$-39.05M
Depreciation and amortization$120K$140K$130K$120K$70K
Stock-based compensation$2.32M$3.75M$4M$4.84M$4.41M
Change in working capital-$-2.32M$840K-$-2.55M$20K$1.7M
Accounts receivable$0.00$3.73M-$-900K-$-2.84M$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.94M-$-2M$720K$2.51M-$-1.58M
Net cash provided by operating activities-$-22.75M-$-19.03M-$-21.78M-$-8.73M-$-32.08M
Investments in property, plant and equipment-$-50K-$-90K-$-50K-$-280K-$-60K
Acquisitions, net$10K$0.00$0.00$700K$0.00
Net cash used for investing activities$4.46M$13.8M-$-4.76M$18.7M$27.4M
Common stock issued$30.4M$160K$0.00$210K$29.9M
Common stock repurchased$0.00$0.00-$-260K$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$30.4M$160K-$-9.23M-$-1.22M$31.1M
Net change in cash$12.2M-$-5.13M-$-35.89M$8.74M$26.4M
Cash at end of period$30.3M$18.1M$23.2M$59.1M$50.4M
Operating cash flow-$-22.75M-$-19.03M-$-21.78M-$-8.73M-$-32.08M
Capital expenditure-$-50K-$-90K-$-50K-$-280K-$-60K
Free cash flow-$-22.79M-$-19.11M-$-21.83M-$-9.01M-$-32.14M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Equillium, Inc.

        Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.

        CEO
        Bruce D. Steel
        Employees
        14
        Beta
        1.77

        Explore

        Frequently asked questions

        What is the intrinsic value of Equillium, Inc. (EQ)?

        InvestorsCraft does not currently publish an intrinsic value for EQ. How the IC value is calculated.

        Is EQ undervalued?

        InvestorsCraft does not publish an undervaluation signal for EQ at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.